Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2025 Net Income-$8.99M-$8.99MN/M vs Q2 2025 EPS Diluted-$0.09-$0.09N/M vs Q2 2025 Operating Income-$9,445,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,757,000N/M ended Dec 31, 2025 · filed Feb 10, 2026 · 41 d after period end